Paul Tudor Jones’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-1,400
Closed -$242K 3671
2026
Q1
$242K Buy
+1,400
New +$260K ﹤0.01% 3266
2025
Q4
Sell
-7,100
Closed -$1.11M 3568
2025
Q3
$1.11M Sell
7,100
-3,300
-32% -$524K ﹤0.01% 2193
2025
Q2
$1.58M Buy
10,400
+3,700
+55% +$493K ﹤0.01% 1830
2025
Q1
$1.01M Buy
6,700
+4,800
+253% +$805K ﹤0.01% 1800
2024
Q4
$351K Buy
1,900
+600
+46% +$116K ﹤0.01% 2483
2024
Q3
$256K Buy
+1,300
New +$270K ﹤0.01% 2403
2023
Q2
Sell
-1,600
Closed -$321K 2505
2023
Q1
$321K Sell
1,600
-4,700
-75% -$1.07M 0.01% 1879
2022
Q4
$1.37M Buy
6,300
+2,500
+66% +$546K 0.03% 875
2022
Q3
$748K Buy
3,800
+2,600
+217% +$561K 0.02% 1124
2022
Q2
$256K Buy
+1,200
New +$293K 0.01% 1668

Other funds holding CRL

Paul Tudor Jones's CRL Position: Q1 2026 in Review

Paul Tudor Jones sold out of Charles River Laboratories (CRL) in Q1 2026, closing a stake of 4,782 shares — an estimated $887K sold.

Paul Tudor Jones first reported a position in CRL in Q2 2013 and held it in 35 quarters. The position peaked at $25.8M in Q2 2025. 559 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Paul Tudor Jones reported no remaining Charles River Laboratories position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 4,782 Charles River Laboratories shares in Q1 2026, an estimated $887K.
  • Paul Tudor Jones first reported a position in Charles River Laboratories in Q2 2013 and held it in 35 quarters.
  • Paul Tudor Jones's Charles River Laboratories position peaked at $25.8M in Q2 2025.
  • 559 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.